Research programme: therapeutic and diagnostic proteins - Trubion/Dyax

Drug Profile

Research programme: therapeutic and diagnostic proteins - Trubion/Dyax

Latest Information Update: 29 Jun 2009

Price : $50

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Dyax; Trubion Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation

Most Recent Events

  • 23 May 2007 Trubion Pharmaceuticals has exercised an option to expand its existing research agreement with Dyax Corp
  • 06 Oct 2006 Early research in Cancer in USA (unspecified route)
  • 06 Oct 2006 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top